On April 27, 2022 HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, reported that clinical trial investigator, Alexander I Spira, MD, PhD, FACP, Co-Director of the Virginia Cancer Specialists (VCS) Research Institute and Director of the Thoracic and Phase I Program, will present a Trials in Progress Poster for HFB200301 on Sunday, June 5 from 8:00 AM to 11:00 AM CT at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting held June 3 – 7, 2022, in Chicago, IL (Press release, HiFiBiO Therapeutics, APR 27, 2022, View Source [SID1234613029]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"HFB200301 is an anti-TNFR2 antibody that induces T cell and natural killer cell activation, demonstrated in preclinical models. The unique mechanism of action indicates that HFB200301 functions as a bridge between innate and adaptive immunity" said Dr. Alexander Spira. "We are excited to have VCS medical staff and patients to be a part of this Phase I clinical study (NCT05238883). Our hospital’s clinical strength combined with HiFiBiO’s innovative DIS approach will hopefully accelerate the clinical development of HFB200301 for cancer patients."
"We look forward to sharing the clinical study for HFB200301, a first-in-class cancer therapeutic targeting TNFR2 as well as our DIS indications selection strategy," said Luigi Manenti, MD, Chief Medical Officer of HiFiBiO Therapeutics. "With strong in-vivo efficacy as a monotherapy and in combination with anti-PD-1 in preclinical models, we believe it has significant potential in DIS selected tumor types including EBV+ gastric cancer, PD-L1+ pleural mesothelioma and clear cell renal cell carcinoma."
Details on the poster presentation are as follows:
Title: Phase I study of HFB200301, a first-in-class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS)
Abstract Number: TPS2670
Poster Session: Developmental Therapeutics – Immunotherapy
Session Date and Time: Poster Session 3 – Sunday, June 5 at 8:00 AM – 11:00 AM CT
The abstract will be available through the ASCO (Free ASCO Whitepaper) Meeting Library at View Source on May 26, 2022.
HFB200301 (TNFR2)
HFB200301 is a first-in-class agonistic anti-TNFR2 antibody that binds potently and selectively to TNFR2 and induces the activation of CD4 T cells, CD8 T cells and NK cells. In vivo, HFB200301 demonstrates potent antitumor activity as a single agent and in combination with anti-PD-1. HiFiBiO is applying a biomarker strategy by leveraging its DIS platform to select indications who may benefit the most from HFB200301 treatment.